Technology Insight: Novel Imaging of Molecular Targets is an Emerging Area Crucial to the Development of Targeted Drugs

Overview

Journal Nat Clin Pract Oncol

Specialty Oncology

Date 2007 Dec 22

PMID 18097456

Citations 28

Authors

Wolfgang A Weber

Johannes Czernin

Michael E Phelps

Harvey R Herschman

Affiliations

Soon will be listed here.

Abstract

Targeted drugs hold great promise for the treatment of malignant tumors; however, there are several challenges for efficient evaluation of these drugs in preclinical and clinical studies. These challenges include identifying the 'correct', biologically active concentration and dose schedule, selecting the patients likely to benefit from treatment, monitoring inhibition of the target protein or pathway, and assessing the response of the tumor to therapy. Although anatomic imaging will remain important, molecular imaging provides several new opportunities to make the process of drug development more efficient. Various techniques for molecular imaging that enable noninvasive and quantitative imaging are now available in the preclinical and clinical settings, to aid development and evaluation of new drugs for the treatment of cancer. In this Review, we discuss the integration of molecular imaging into the process of drug development and how molecular imaging can address key questions in the preclinical and clinical evaluation of new targeted drugs. Examples include imaging of the expression and inhibition of drug targets, noninvasive tissue pharmacokinetics, and early assessment of the tumor response.

Citing Articles

Switching the NIR upconversion of nanoparticles for the orthogonal activation of photoacoustic imaging and phototherapy.

Yang Y, Huang J, Wei W, Zeng Q, Li X, Xing D Nat Commun. 2022; 13(1):3149.

PMID: 35672303 PMC: 9174188. DOI: 10.1038/s41467-022-30713-w.

The Unique Pharmacometrics of Small Molecule Therapeutic Drug Tracer Imaging for Clinical Oncology.

Dunphy M, Pillarsetty N Cancers (Basel). 2020; 12(9).

PMID: 32971780 PMC: 7563483. DOI: 10.3390/cancers12092712.

Spectral Photon-Counting Molecular Imaging for Quantification of Monoclonal Antibody-Conjugated Gold Nanoparticles Targeted to Lymphoma and Breast Cancer: An Study.

Moghiseh M, Lowe C, Lewis J, Kumar D, Butler A, Anderson N Contrast Media Mol Imaging. 2019; 2018:2136840.

PMID: 30662379 PMC: 6312585. DOI: 10.1155/2018/2136840.

Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model.

Kim J, Choi S, Ham S, Cho Y, Lee S, Kang J PLoS One. 2018; 13(1):e0187063.

PMID: 29370209 PMC: 5784895. DOI: 10.1371/journal.pone.0187063.

Multimodality molecular imaging of the lung.

Chen D, Kinahan P Clin Transl Imaging. 2017; 2(5):391-401.

PMID: 28164069 PMC: 5289702. DOI: 10.1007/s40336-014-0084-9.

References

Hutchinson O, Collingridge D, Barthel H, Price P, Aboagye E . Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography. Curr Pharm Des. 2003; 9(11):917-29. DOI: 10.2174/1381612033455288. View

Hsueh W, Kesner A, Gangloff A, Pegram M, Beryt M, Czernin J . Predicting chemotherapy response to paclitaxel with 18F-Fluoropaclitaxel and PET. J Nucl Med. 2006; 47(12):1995-9. View

Ntziachristos V, Ripoll J, Wang L, Weissleder R . Looking and listening to light: the evolution of whole-body photonic imaging. Nat Biotechnol. 2005; 23(3):313-20. DOI: 10.1038/nbt1074. View

Jayson G, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M . Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst. 2002; 94(19):1484-93. DOI: 10.1093/jnci/94.19.1484. View

Luker K, Smith M, Luker G, Gammon S, Piwnica-Worms H, Piwnica-Worms D . Kinetics of regulated protein-protein interactions revealed with firefly luciferase complementation imaging in cells and living animals. Proc Natl Acad Sci U S A. 2004; 101(33):12288-93. PMC: 514471. DOI: 10.1073/pnas.0404041101. View

Hofmann M, Maecke H, BORNER R, Weckesser E, Schoffski P, Oei L . Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001; 28(12):1751-7. DOI: 10.1007/s002590100639. View

Schottelius M, Poethko T, Herz M, Reubi J, Kessler H, Schwaiger M . First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin Cancer Res. 2004; 10(11):3593-606. DOI: 10.1158/1078-0432.CCR-03-0359. View

Shepherd F, Pereira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S . Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353(2):123-32. DOI: 10.1056/NEJMoa050753. View

Nunn A . The cost of developing imaging agents for routine clinical use. Invest Radiol. 2006; 41(3):206-12. DOI: 10.1097/01.rli.0000191370.52737.75. View

10.

Su H, Bodenstein C, Dumont R, Seimbille Y, Dubinett S, Phelps M . Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2006; 12(19):5659-67. DOI: 10.1158/1078-0432.CCR-06-0368. View

11.

Sharma P, Brown S, Walter G, Santra S, Moudgil B . Nanoparticles for bioimaging. Adv Colloid Interface Sci. 2006; 123-126:471-85. DOI: 10.1016/j.cis.2006.05.026. View

12.

Ntziachristos V, Tung C, Bremer C, Weissleder R . Fluorescence molecular tomography resolves protease activity in vivo. Nat Med. 2002; 8(7):757-60. DOI: 10.1038/nm729. View

13.

Blodgett T, Meltzer C, Townsend D . PET/CT: form and function. Radiology. 2007; 242(2):360-85. DOI: 10.1148/radiol.2422051113. View

14.

Van Den Abbeele A, Badawi R . Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer. 2003; 38 Suppl 5:S60-5. DOI: 10.1016/s0959-8049(02)80604-9. View

15.

Workman P, Aboagye E, Chung Y, Griffiths J, Hart R, Leach M . Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst. 2006; 98(9):580-98. DOI: 10.1093/jnci/djj162. View

16.

Wu A, Senter P . Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005; 23(9):1137-46. DOI: 10.1038/nbt1141. View

17.

Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L . Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med. 2005; 46(6):945-52. View

18.

Lee C, Sui G, Elizarov A, Shu C, Shin Y, Dooley A . Multistep synthesis of a radiolabeled imaging probe using integrated microfluidics. Science. 2005; 310(5755):1793-6. DOI: 10.1126/science.1118919. View

19.

Dehdashti F, Flanagan F, Mortimer J, Katzenellenbogen J, Welch M, Siegel B . Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med. 1999; 26(1):51-6. DOI: 10.1007/s002590050359. View

20.

Bremer C, Tung C, Weissleder R . In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med. 2001; 7(6):743-8. DOI: 10.1038/89126. View